Subgroup analysis demonstrated that neratinib gave greater benefit to patients with HR+ breast cancer than to those with HR− breast cancer, suggesting that there might be a preferential effect of TKIs on targeting the interaction of ER and HER2 than does the continuation of trastuzumab with endocrine treatment (Chan et al. 2016). This evidence concerns the gene ERBB2 and breast carcinoma.